Who
Lee Kalowski
CFO and President
Company insider
Files Form 4 as: CFO and President, Q32 Bio; President and CFO, Bicycle Therapeutics; Chief Financial Officer, Eledon Pharmaceuticals.
In numbers
- Trades disclosed
- 70
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $3.2M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 17 Sep 2014
- Last trade
- 6 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 14 Oct 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $11K1,301 at $8.32 | filing |
| 25 Aug 2026filed 27 Aug 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $66K3,972 at $16.56 | filing |
| 25 Aug 2026filed 27 Aug 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $66K3,972 at $16.56 | filing |
| 16 Jul 2026filed 20 Jul 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 25 Feb 2026filed 27 Feb 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $18K3,995 at $4.51 | filing |
| 25 Feb 2026filed 27 Feb 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $18K3,995 at $4.51 | filing |
| 24 Feb 2026filed 20 Mar 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 24 Feb 2026filed 20 Mar 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 2 Dec 2025filed 4 Dec 2025 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $31K9,072 at $3.46 | filing |
| 26 Aug 2025filed 28 Aug 2025 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $7,6324,240 at $1.80 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —16,901 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —16,901 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —161,323 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —161,323 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 25 Mar 2024filed 27 Mar 2024 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —161,323 at $0.00 | filing |
| 3 Apr 2023filed 5 Apr 2023 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,937376 at $21.11 | filing |
| 3 Jan 2023filed 5 Jan 2023 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
News
Head to Head Review: Q32 Bio (NASDAQ:QTTB) vs. Applied Therapeutics (NASDAQ:APLT)QTTB · tickerreport.com · 15 Oct 2026Head to Head Review: Kyntra Bio (NASDAQ:KYNB) and Q32 Bio (NASDAQ:QTTB)QTTB · tickerreport.com · 12 Oct 2026Contrasting Q32 Bio (NASDAQ:QTTB) and Kyntra Bio (NASDAQ:KYNB)QTTB · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Lee Kalowski; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.